Johns Hopkins

Johns Hopkins University researchers have developed a method called targeted error correction sequencing, or TEC-Seq, to increase liquid biopsy sensitivity.

Such analyses can help researchers pinpoint how various cancers evolve and determine the best kinds of tests to use to find certain disease information.

Speakers at the conference's opening plenary showed how their work in cancer research fit into the broad theme of 'Discover, Predict, Prevent, Treat.'

Qiagen will commercialize its research-use-only AdnaTest to detect AR-V7 from liquid biopsies to investigate resistance to drugs for advanced prostate cancer.

The technology, called Tunr, involves targeting translation elongation by introducing consecutive adenosine nucleotides into a gene coding sequence of interest.

The researchers also reported that the percentage of mutations attributable to replication errors, environmental exposures, and heredity varied by organ.

With new research and commercial test launches, clincians anticipate exciting new tools but judging quality and utility has become challenging.

The legal battle began last fall when LabCorp subsidiary Esoterix and Johns Hopkins University sued Myriad alleging infringement of four patents. 

International research teams collaborated to create five fully functioning synthetic yeast chromosomes, taking them one step closer to a whole synthetic genome.

Wealth in the Genes?

A trio of economists writes that, even after controlling for socio-economic factors, there's a relationship between genes and wealth, Fortune reports.

Pages

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.